Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7001980 | 0.99 | MAPT (0.46) | MAPTKDM4EGAAPARP1ADORA1 | |
| SCHEMBL7001675 | 0.85 | L3MBTL1 (0.46) | MAPTKDM4EADORA1ADORA2AADORA3 | |
| SCHEMBL7001981 | 0.84 | L3MBTL1 (0.48) | MAPTKDM4EGAAADORA1ADORA2A | |
| SCHEMBL7003936 | 0.82 | BRD4 (0.42) | MAPTKDM4EGAAADORA1ALDH1A1 | |
| SCHEMBL7003811 | 0.81 | BRD4 (0.44) | MAPTKDM4EGAAALDH1A1KMT2A | |
| SCHEMBL6995164 | 0.76 | MAPK13 (0.43) | MAPTKDM4EGAATP53ALDH1A1 | |
| SCHEMBL7000118 | 0.73 | ADORA3 (0.49) | GAAADORA1ADORA2AADORA3TP53 | |
| SCHEMBL7006143 | 0.72 | MAPK13 (0.47) | MAPTKDM4EGAAPARP1ALDH1A1 | |
| SCHEMBL7001239 | 0.72 | MAPK13 (0.43) | MAPTKDM4EGAAALDH1A1KMT2A | |
| SCHEMBL7002540 | 0.71 | MAPK13 (0.42) | MAPTKDM4EALDH1A1KMT2AMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140938-B1 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | UNIV PRINCETON (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1321467-A2 | High affinity inhibitors for target validation and uses thereof | Princeton University (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | PRINCETON UNIVERSITY | 2003-04-17 | — | — | US | disclosed |
| US-6383790-B1 | PYRAZOLO(3,4-D)PYRIMIDINE BASED COMPOUND; ANTICARCINOGENIC AGENTS; ANTITUMOR AGENTS | PRINCETON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
| EP-1140938-A2 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | Princeton University (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042042-A2 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | PRINCETON UNIVERSITY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | SRC, MARCKS, TEC | MAPT 3225/4885KDM4E 1129/4885GAA 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.